​A New Milestone for 露美瑞 Lumirix® in Taiwan

A New Treatment Choice for Vitiligo Patients in Taiwan Is Now Moving into Real-World Use

We are pleased to share another important milestone for Lumirix® (ruxolitinib) cream 露美瑞乳膏 15mg/g in Taiwan.

Following its recent regulatory approval, Lumirix® recorded its first commercial order in Taiwan on 09 September 2026, marking an important transition from regulatory approval to real-world clinical access.

Lumirix® is a topical, non-steroidal treatment containing ruxolitinib, a JAK1/JAK2 inhibitor, offering an additional treatment option for eligible patients aged 12 years and above with non-segmental vitiligo.

For patients living with vitiligo, this means that a new treatment option is beginning to move beyond approval and into actual clinical practice in Taiwan.

The availability of Lumirix® expands treatment options for eligible patients, providing dermatologists and their patients with an additional therapeutic option.

This milestone reflects an important part of our mission at Rxilient Health: not only to bring innovative medicines to emerging markets, but also to help translate innovation into meaningful patient access.

Approval is an important first step.

Access is what brings innovation closer to patients.

We are proud to see Lumirix® begin its journey into real-world use in Taiwan and look forward to working closely with healthcare professionals and partners to support broader patient access in the future.